Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo

NCT07595939 · tracked via the Priya Life Science China tracker

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Phase

Phase 3

Started

2026-06-01

Last updated

2026-05-19

Condition(s) studied

Vitiligo

Investigational drug(s) / intervention(s)

Ruxolitinib 1.5% Cream BID

Ruxolitinib 1.5% Cream BID: In this single-arm clinical trial, all eligible subjects will receive the same investigational intervention. The study drug is Ruxolitinib Phosphate Cream, 1.5% (w/w), supplied in 100 g tubes. The dosing regimen consists of applying a thin layer of the cream to all vitiligo lesions twice daily, with approximately 12 hours between applications. Throughout the treatment period, the total application area must not exceed 10% of the Body Surface Area, and the maximum usage is limited to two tubes (totaling 200 g) per month. The entire investigational intervention will last for 24 weeks, unless a subject meets early discontinuation criteria beforehand. It must be emphasized that this drug is for cutaneous use only and is strictly prohibited for application to mucous membranes (e.g., inside the mouth, vagina) or in or around the eyes.

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Ruxolitinib Phosphate Cream in treating non-segmental vitiligo in children aged 2 to 11 years under real-world conditions. The main question\[s\] it aims to answer are:

Primary Efficacy: What is the improvement rate (e.g., proportion of participants achieving F-VASI75) after 24 weeks of treatment with Ruxolitinib Phosphate Cream in this population? Safety Profile: What is the safety profile of the treatment over 24 weeks, specifically regarding the incidence of Application Site Acne, Application Site Pruritus, and other adverse events?

Participants will:

Apply Ruxolitinib Phosphate Cream topically to vitiligo lesions as prescribed by the investigator.

Attend scheduled clinic visits at Weeks 4, 8, 12, and 24 for efficacy and safety assessments.

Undergo standardized clinical photography and severity scoring of their vitiligo lesions at each visit.

Report any adverse events or skin reactions experienced during the study period to the research team.

Eligibility

Sex

ALL

Min age

2 Years

Max age

11 Years

Healthy volunteers

Inclusion Criteria: * Children aged 2 to 11 years, regardless of sex. * Clinical diagnosis of non-segmental vitiligo, with affected Body Surface Area (BSA) ≥0.1%, T-VASI score ≥0.1, and total depigmented area not exceeding 10% BSA. * Legal guardian voluntarily provides signed informed consent and agrees to scheduled follow-ups. Exclusion Criteria: * Diagnosis of other forms of vitiligo (e.g., segmental vitiligo). * Presence of other hypopigmentary or depigmentary disorders that could interfere with efficacy assessment (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus depigmentosus, and tinea versicolor). * Prior or current use of any treatment for depigmentation. * History of failure with any systemic or topical JAK inhibitor therapy for vitiligo or any other inflammatory condition. * Known hypersensitivity to the study drug or its excipients. * Concurrent participation in another clinical trial. * Considered by the investigator to be unsuitable for the study for any other reason.

Primary outcome measure(s)

Total-Vitiligo Area Scoring Index (T-VASI) — 24 week
Improvement from baseline in the Total Vitiligo Area Scoring Index (T-VASI) at Week 24. The T-VASI ranges from 0 to 100, with higher scores indicating worse outcome (greater depigmentation).

Trial sites (1)

Facility	City	Region	Status
Children's Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang

More The Children's Hospital of Zhejiang University School of Medicine trials in China

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE Recruiting

Clinical Effectiveness of Non-contact Heart Rate and Respiratory Rate Monitoring System Active, not recruiting

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases Recruiting

Urethral Plate Flap vs. Tunica Vaginalis Flap for Residual Severe Ventral Curvature in Hypospadias Starting soon

Other trials for the same condition

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo Recruiting

A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo Recruiting

Study of D-2570 in Subjects With Non-Segmental Vitiligo Recruiting

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Active, not recruiting

Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07595939 on ClinicalTrials.gov ↗ ← All trials in China